[Skip to Content]

Avastin

New Eye Journal Collection: Avastin and Wet AMD

Eye, the journal of The Royal College of Ophthalmologists, has this week published their online collection drawing together papers published on Avastin and Wet AMD in 2018. Members will no doubt be aware of the issue, and ongoing work by the College in campaigning since 2012 for the use of Avastin in treatment for wet

New NICE Age Related Macular Degeneration guidance supports potential cost savings for the NHS

NHS Clinical Commissioners (NHSCC) and The Royal College of Ophthalmologists (RCOphth) welcome the publication today of guidance from the National Institute for Health and Care Excellence (NICE) which we believe can help to secure better value from the significant funds currently being spent on treating wet age related macular degeneration (AMD). In the current NHS

Use of Avastin (bevacizumab) in age related macular degeneration

Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no

RCOphth recommends appraisal of the use of bevacizumab (Avastin) for age related macular degeneration

The Royal College of Ophthalmologists recommends UK regulatory bodies appraise the use of bevacizumab (Avastin) for age related macular degeneration potentially saving the NHS over £100million a year Age related macular degeneration (AMD) is the commonest cause of blindness among elderly people in the developed world1. The ageing population in the UK and associated eye